Chong Kun Dang said it would export Nesbell, an anemia treatment biosimilar (Original: Nesp), to six Middle East countries, through Menagen, an Omani pharmaceutical company.
Under the contract, Chong Kun Dang will supply finished Nesbell products to Menagen and receive a down payment and milestones for each development stage. However, the company did not disclose the size of the contract. Menagen plans to sell Nesbell exclusively to six countries in the Middle East — Oman, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, and Bahrain.
Nesbell, released in Korea and Japan in 2019, is a second-generation anemia biosimilar of novel erythropoiesis stimulating protein (NESP) co-developed by Japan’s Kyowa Hakko Kirin and Amgen, a U.S. company. It treats anemia of chronic diseases associated with cancer.
Compared to the first generation of drugs, the treatment significantly reduced the frequency of drug administration by using genetic engineering techniques.
Chong Kun Dang is also working on marketing the drug approval in three Southeast Asian countries — Taiwan, Vietnam, and Thailand – after signing an export contract with Lotus, a firm in charge of global pharmaceutical company Alvogen’s marketing in the Asian region.
“We have managed to prove the excellence of our products in the global market as we will now export the treatment to the Middle East, following Japan and Southeast Asia,” a company official said. “In the future, the company plans to target the global Nesp market, including Europe and the U.S.”